---
title: "CLRB.US (CLRB.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CLRB.US/news.md"
symbol: "CLRB.US"
name: "CLRB.US"
parent: "https://longbridge.com/en/quote/CLRB.US.md"
datetime: "2026-03-13T09:11:42.857Z"
locales:
  - [en](https://longbridge.com/en/quote/CLRB.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CLRB.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CLRB.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/CLRB.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/CLRB.US/news.md)


# CLRB.US (CLRB.US) — Related News

### [](https://longbridge.com/en/news/278598231.md)
*2026-03-10T17:42:05.000Z*
> Cellectar Biosciences shares are trading higher after Maxim Group upgraded the stock from Hold to Buy rating and announc

### [Cellectar Bioscience | 8-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/277778186.md)
*2026-03-04T12:25:38.000Z*
### [Cellectar Biosciences 2025 10-K — Net loss $8.35 EPS; no revenue reported](https://longbridge.com/en/news/277778414.md)
*2026-03-04T12:25:01.000Z*
> Cellectar Biosciences reported a net loss of $21.79 million, or $8.35 per share, for the year ended December 31, 2025, w

### [Cellectar Bioscience | 10-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/277778161.md)
*2026-03-04T12:24:25.000Z*
### [Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates | CLRB Stock News](https://longbridge.com/en/news/277777785.md)
*2026-03-04T04:15:00.000Z*
> Cellectar Biosciences reported its financial results for the year ended December 31, 2025, highlighting significant corp

### [Insights into Cellectar Biosciences's Upcoming Earnings](https://longbridge.com/en/news/277672373.md)
*2026-03-03T20:01:36.000Z*
> Cellectar Biosciences (NASDAQ:CLRB) is set to announce its quarterly earnings on March 4, 2026, with analysts predicting

### [Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 | CLRB Stock News](https://longbridge.com/en/news/276892215.md)
*2026-02-25T05:05:00.000Z*
> Cellectar Biosciences, Inc. (NASDAQ: CLRB) will report its full year financial results for 2025 and provide a corporate 

### [Primary sclerosing cholangitis market expected to grow 2025-2034 with emerging therapies like LB-P8, Volixibat, IQIRVO.](https://longbridge.com/en/news/275042849.md)
*2026-02-05T22:32:26.000Z*
> DelveInsight's analysis predicts significant growth in the primary sclerosing cholangitis market from 2025 to 2034. This